603566 Stock Overview
Engages in the research and development, production, and marketing of veterinary biological products and drugs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Pulike Biological Engineering, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.73 |
| 52 Week High | CN¥25.00 |
| 52 Week Low | CN¥12.89 |
| Beta | 0.24 |
| 1 Month Change | -30.09% |
| 3 Month Change | -11.69% |
| 1 Year Change | -39.80% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603566 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.0% | -1.1% | 0.06% |
| 1Y | -39.8% | -12.5% | -16.1% |
Return vs Industry: 603566 underperformed the CN Pharmaceuticals industry which returned -12.5% over the past year.
Return vs Market: 603566 underperformed the CN Market which returned -16.1% over the past year.
Price Volatility
| 603566 volatility | |
|---|---|
| 603566 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 603566's share price has been volatile over the past 3 months.
Volatility Over Time: 603566's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,679 | Wei Hu | www.pulike.com.cn |
Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company was founded in 1995 and is headquartered in Luoyang, China.
Pulike Biological Engineering, Inc. Fundamentals Summary
| 603566 fundamental statistics | |
|---|---|
| Market cap | CN¥5.08b |
| Earnings (TTM) | CN¥137.79m |
| Revenue (TTM) | CN¥1.18b |
36.8x
P/E Ratio4.3x
P/S RatioIs 603566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603566 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.18b |
| Cost of Revenue | CN¥445.63m |
| Gross Profit | CN¥735.64m |
| Other Expenses | CN¥597.86m |
| Earnings | CN¥137.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.40 |
| Gross Margin | 62.28% |
| Net Profit Margin | 11.66% |
| Debt/Equity Ratio | 0% |
How did 603566 perform over the long term?
See historical performance and comparison